Stockscreener 앱 받기
7.64
2.55%
-0.20
시간 외 거래:
7.64
전일 마감가:
$7.84
열려 있는:
$7.93
하루 거래량:
310.19K
Relative Volume:
1.82
시가총액:
$163.33M
수익:
$66.59M
순이익/손실:
$-104.93M
주가수익비율:
-1.5434
EPS:
-4.95
순현금흐름:
$-96.48M
1주 성능:
-7.73%
1개월 성능:
-8.94%
6개월 성능:
+18.63%
1년 성능:
-32.39%
1일 변동 폭
$7.55
$7.968
1주일 범위
$7.28
$8.35
52주 변동 폭
$4.09
$13.37
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
명칭
Enanta Pharmaceuticals Inc
전화
617 607 0800
주소
4 KINGSBURY AVENUE, WATERTOWN, MA
ENTA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
7.64 | 167.60M | 66.59M | -104.93M | -96.48M | -4.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.12 | 99.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.99 | 63.46B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.56 | 59.27B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
736.76 | 44.78B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
334.40 | 37.75B | 3.81B | -644.79M | -669.77M | -6.24 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-28 | 재개 | H.C. Wainwright | Buy |
| 2023-08-09 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-08-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-12-09 | 개시 | H.C. Wainwright | Buy |
| 2022-07-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2022-06-01 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-09-09 | 개시 | SVB Leerink | Mkt Perform |
| 2021-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-11-24 | 개시 | Evercore ISI | Underperform |
| 2020-08-28 | 재개 | ROTH Capital | Buy |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-07-27 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2020-03-17 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-11-22 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-26 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-05-24 | 개시 | Wolfe Research | Outperform |
| 2019-04-23 | 업그레이드 | Berenberg | Hold → Buy |
| 2018-12-13 | 개시 | Berenberg | Hold |
| 2018-06-06 | 개시 | ROTH Capital | Buy |
| 2018-02-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-01-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-11-21 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-07-11 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2016-04-28 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 재확인 | Barclays | Underweight |
| 2015-10-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2015-10-23 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
모두보기
Enanta Pharmaceuticals Inc 주식(ENTA)의 최신 뉴스
Quantitative breakdown of Enanta Pharmaceuticals Inc. recent move2025 Winners & Losers & Comprehensive Market Scan Insights - newser.com
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Evercore ISI Lowers Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target to $12.00 - MarketBeat
Signal strength of Enanta Pharmaceuticals Inc. stock in tech scannersJuly 2025 Decliners & High Return Stock Watch Alerts - newser.com
Valuation Update: Can Enanta Pharmaceuticals Inc reach all time highs this yearJuly 2025 Institutional & Long-Term Safe Return Strategies - khodrobank.com
Earnings visualization tools for Enanta Pharmaceuticals Inc.Market Performance Report & Daily Market Momentum Tracking - newser.com
Best data tools to analyze Enanta Pharmaceuticals Inc. stockQuarterly Market Summary & Free High Accuracy Swing Entry Alerts - newser.com
Is Enanta Pharmaceuticals Inc. showing signs of accumulationTrade Entry Report & Safe Capital Growth Plans - newser.com
How moving averages guide Enanta Pharmaceuticals Inc. tradingMarket Activity Recap & Risk Managed Trade Strategies - newser.com
Aug Drivers: Can Enanta Pharmaceuticals Inc be recession proof2025 Market Trends & Weekly Market Pulse Alerts - khodrobank.com
Is now a turning point for Enanta Pharmaceuticals Inc.Market Growth Report & Entry Point Confirmation Alerts - newser.com
Enanta Pharmaceuticals Inc. stock retracement – recovery analysisQuarterly Portfolio Summary & Community Verified Watchlist Alerts - newser.com
Risk Hedge: Whats the outlook for Enanta Pharmaceuticals Incs sector2025 Fundamental Recap & Weekly Market Pulse Updates - khodrobank.com
Analyzing Enanta Pharmaceuticals Inc. with risk reward ratio chartsWeekly Loss Report & Low Drawdown Investment Ideas - newser.com
How to read the order book for Enanta Pharmaceuticals Inc.Quarterly Portfolio Summary & Growth-Oriented Investment Plans - newser.com
Can Enanta Pharmaceuticals Inc sustain earnings growthWeekly Volume Report & Reliable Entry Point Trade Alerts - khodrobank.com
Primary Biliary Cholangitis Market Expected to Gain Momentum Through 2034, According to DelveInsight | Intercept Pharma, Enanta Pharma, COUR Pharma, Novartis, Gannex Pharma, Nanjing Chia-tai Tianqing - Barchart.com
Trade Recap: Why is Enanta Pharmaceuticals Inc stock going upQuarterly Profit Summary & Weekly Consistent Profit Watchlists - khodrobank.com
Using AI based signals to follow Enanta Pharmaceuticals Inc.Portfolio Performance Summary & Community Trade Idea Sharing - newser.com
Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target Lowered to $12.00 at Evercore ISI - Defense World
Day Trade: Is AACTWS forming bullish engulfing patternsLong Setup & AI Enhanced Trading Signals - خودرو بانک
Aug Fed Impact: Is Enanta Pharmaceuticals Inc. stock a smart retirement pickJuly 2025 Summary & Detailed Earnings Play Alerts - khodrobank.com
Evercore ISI Group Lowers Price Target for Enanta Pharma (ENTA) | ENTA Stock News - GuruFocus
How to recover losses in Enanta Pharmaceuticals Inc. stockGold Moves & Short-Term Swing Trade Alerts - newser.com
Institutional scanner results for Enanta Pharmaceuticals Inc.IPO Watch & AI Driven Stock Reports - newser.com
Acadian Asset Management LLC Increases Position in Enanta Pharmaceuticals, Inc. $ENTA - Defense World
Enanta Pharmaceuticals Inc (ENTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.43%
0.09%
자본화:
|
볼륨(24시간):